Ok the insiders must have known yesterday , no big deal to get approval to do a trial taking several more years.
"OncoPac-1 Study is expected to enrol the first subject in early 2017 and recruitment is anticipated to take approximately 2 years, with each patient to be followed until disease progression. Subjects are then followed for overall survival until death, or until the last enrolled study patient has completed 52 weeks of overall survival follow-up."
- Forums
- ASX - By Stock
- Ann: FDA IDE Approval-OSL.AX
OSL
oncosil medical ltd
Add to My Watchlist
0.00%
!
$1.23

Ok the insiders must have known yesterday , no big deal to get...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.23 |
Change
0.000(0.00%) |
Mkt cap ! $17.49M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3591 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.24 | 800 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 3591 | 1.250 |
2 | 15 | 1.230 |
1 | 1323 | 1.200 |
1 | 3500 | 1.190 |
1 | 90 | 1.160 |
Price($) | Vol. | No. |
---|---|---|
1.240 | 800 | 1 |
1.250 | 60000 | 1 |
1.500 | 15 | 1 |
1.600 | 19150 | 1 |
0.000 | 0 | 0 |
Last trade - 09.22am 27/06/2025 (20 minute delay) ? |
Featured News
OSL (ASX) Chart |
Day chart unavailable
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online